198 related articles for article (PubMed ID: 10714789)
1. Evidence-based medicine: empiric antibiotic therapy in community-acquired pneumonia.
Read RC
J Infect; 1999 Nov; 39(3):171-8. PubMed ID: 10714789
[TBL] [Abstract][Full Text] [Related]
2. Macrolides are ideal for empiric therapy of community-acquired pneumonia in the immunocompetent host.
Vergis EN; Yu VL
Semin Respir Infect; 1997 Dec; 12(4):322-8. PubMed ID: 9436959
[TBL] [Abstract][Full Text] [Related]
3. Antimicrobial resistance in Streptococcus pneumoniae: implications for patients with community-acquired pneumonia.
Chenoweth CE; Saint S; Martinez F; Lynch JP; Fendrick AM
Mayo Clin Proc; 2000 Nov; 75(11):1161-8. PubMed ID: 11075746
[TBL] [Abstract][Full Text] [Related]
4. Empiric therapy of community-acquired pneumonia: guidelines for the perplexed?
Cunha BA
Chest; 2004 May; 125(5):1913-9. PubMed ID: 15136407
[TBL] [Abstract][Full Text] [Related]
5. [Community acquired pneumonia; no reason to revise current Dutch antibiotic guidelines].
Oosterheert JJ; Bonten MJ; Schneider MM; Hoepelman IM
Ned Tijdschr Geneeskd; 2003 Mar; 147(9):381-6. PubMed ID: 12661455
[TBL] [Abstract][Full Text] [Related]
6. Community-acquired lower respiratory tract infections: etiology and treatment.
Guthrie R
Chest; 2001 Dec; 120(6):2021-34. PubMed ID: 11742937
[TBL] [Abstract][Full Text] [Related]
7. Advances in antibiotic therapy for community-acquired pneumonia.
Viasus D; Garcia-Vidal C; Carratalà J
Curr Opin Pulm Med; 2013 May; 19(3):209-15. PubMed ID: 23422416
[TBL] [Abstract][Full Text] [Related]
8. The impact of empiric antimicrobial therapy with a β-lactam and fluoroquinolone on mortality for patients hospitalized with severe pneumonia.
Mortensen EM; Restrepo MI; Anzueto A; Pugh J
Crit Care; 2005 Dec; 10(1):R8. PubMed ID: 16420641
[TBL] [Abstract][Full Text] [Related]
9. Guideline-concordant antibiotic use and survival among patients with community-acquired pneumonia admitted to the intensive care unit.
Frei CR; Attridge RT; Mortensen EM; Restrepo MI; Yu Y; Oramasionwu CU; Ruiz JL; Burgess DS
Clin Ther; 2010 Feb; 32(2):293-9. PubMed ID: 20206787
[TBL] [Abstract][Full Text] [Related]
10. Empiric treatment in hospitalized community-acquired pneumonia. Impact on mortality, length of stay and re-admission.
Reyes Calzada S; Martínez Tomas R; Cremades Romero MJ; Martínez Moragón E; Soler Cataluña JJ; Menéndez Villanueva R
Respir Med; 2007 Sep; 101(9):1909-15. PubMed ID: 17628462
[TBL] [Abstract][Full Text] [Related]
11. Usefulness of betalactam therapy for community-acquired pneumonia in the era of drug-resistant Streptococcus pneumoniae: a randomized study of amoxicillin-clavulanate and ceftriaxone.
Rosón B; Carratalà J; Tubau F; Dorca J; Liñares J; Pallares R; Manresa F; Gudiol F
Microb Drug Resist; 2001; 7(1):85-96. PubMed ID: 11310807
[TBL] [Abstract][Full Text] [Related]
12. Clinical relevance of antimicrobial resistance in the management of pneumococcal community-acquired pneumonia.
Feldman C
J Lab Clin Med; 2004 May; 143(5):269-83. PubMed ID: 15122171
[TBL] [Abstract][Full Text] [Related]
13. Macrolides vs. quinolones for community-acquired pneumonia: meta-analysis of randomized controlled trials.
Skalsky K; Yahav D; Lador A; Eliakim-Raz N; Leibovici L; Paul M
Clin Microbiol Infect; 2013 Apr; 19(4):370-8. PubMed ID: 22489673
[TBL] [Abstract][Full Text] [Related]
14. How long should we treat community-acquired pneumonia?
Scalera NM; File TM
Curr Opin Infect Dis; 2007 Apr; 20(2):177-81. PubMed ID: 17496577
[TBL] [Abstract][Full Text] [Related]
15. Solithromycin for the treatment of community-acquired bacterial pneumonia.
Viasus D; Ramos O; Ramos L; Simonetti AF; Carratalà J
Expert Rev Respir Med; 2017 Jan; 11(1):5-12. PubMed ID: 27753516
[TBL] [Abstract][Full Text] [Related]
16. Principles of Antibiotic Management of Community-Acquired Pneumonia.
Bender MT; Niederman MS
Semin Respir Crit Care Med; 2016 Dec; 37(6):905-912. PubMed ID: 27960214
[TBL] [Abstract][Full Text] [Related]
17. Diagnosis and management of community-acquired pneumonia in adults.
Watkins RR; Lemonovich TL
Am Fam Physician; 2011 Jun; 83(11):1299-306. PubMed ID: 21661712
[TBL] [Abstract][Full Text] [Related]
18. Antibiotic treatment of moderate-severe community-acquired pneumonia: design and rationale of a multicentre cluster-randomised cross-over trial.
van Werkhoven CH; Postma DF; Oosterheert JJ; Bonten MJ
Neth J Med; 2014 Apr; 72(3):170-8. PubMed ID: 24846935
[TBL] [Abstract][Full Text] [Related]
19. Effect of macrolides as part of initial empiric therapy on length of stay in patients hospitalized with community-acquired pneumonia.
Stahl JE; Barza M; DesJardin J; Martin R; Eckman MH
Arch Intern Med; 1999 Nov; 159(21):2576-80. PubMed ID: 10573047
[TBL] [Abstract][Full Text] [Related]
20. Clinical failure with and without empiric atypical bacteria coverage in hospitalized adults with community-acquired pneumonia: a systematic review and meta-analysis.
Eljaaly K; Alshehri S; Aljabri A; Abraham I; Al Mohajer M; Kalil AC; Nix DE
BMC Infect Dis; 2017 Jun; 17(1):385. PubMed ID: 28576117
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
